A human monoclonal scFv-Fc antibody targeting the glycoprotein (GP) of Zaire Ebolavirus has been developed. The envelope glycoprotein is processed into two subunits, GP1 and GP2, while the transmembrane and cytoplasmic domains have been eliminated. The immunogen includes a C-terminal linker and a hexahistidine tag sequence (GSGHHHHHH). GP1 plays a crucial role in binding to receptors on host cells, specifically interacting with CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are essential cofactors for viral entry. The binding of GP1 to CD209 on dendritic cells (DCs) and to CLEC4M on the endothelial cells of liver sinusoids and lymph node sinuses enhances the infection process of macrophages and endothelial cells.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for VS-0125-FY115. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.